Hematology / Oncology CE Activities

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

1.25 CE Credit(s)

Closing the Gap: Personalized Approaches to Cervical Cancer Screening and Treatment

0.5 CE Credit(s)

Exploring the Role of Novel Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

0.5 CE Credit(s)

Identifying a Clear Path Through the Changing Maze of AML Management

0.75 CE Credit(s)

Navigating the Frontier of Hematologic Malignancy Therapies. Series of 5 Modules

3.00 CE Credit(s)

Cell-Free DNA Potential in Guiding Therapies and Q&A – Module 5

1.0 CE Credit(s)

PROTACs: A Paradigm Shift in Drug Discovery – Module 3

CE Credit Expired

Novel ADC Target Hunting in Pediatric AML – Module 4

0.5 CE Credit(s)

Hematology / oncology blog

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.

Hematology / Oncology
Blog

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).

Hematology / Oncology
Blog

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.

Hematology / Oncology
Blog

RMEI Presentations

Optimizing treatment in BCC and CSCC: 3 years of oncology CME

Iterative Data-Driven Education for Evolving Strategies of Care in cSCC

When the Patient Voice is Heard in Education, Does the Clinician Listen?

RMEI DECISION SUPPORT AIDS

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

In late 2022, the ocular implant, insertion tool assembly, (including the drug vial & initial fill needle) for ranibizumab PDS were voluntarily recalled due to septum dislodgement and paused implantations including ongoing global clinical trials; this did not include the refill vial and needle.

Hematology / Oncology
Decision Support Aid

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.

Hematology / Oncology
Decision Support Aid

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

Latest Hematology / Oncology Articles

Drug-Induced Oxidative Hemolysis April 25, 2024
A 57-year-old woman presented with a 3-day history of shortness of breath and dizziness. Laboratory studies showed severe anemia with hemolysis, along with cellular abnormalities in peripheral blood.
Wing Kit Lam, Sze Fai Yip
Intention to Treat: CAR T-Cells and Safety Signals — ITT Episode 29 April 25, 2024
This podcast episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers.
CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia April 25, 2024
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with relapsed or refractory B-cell lymphoid cancers.1 With studies showing that more than 50% of patients had an objective response and that half these patients had sustained disease-free survival, up to 10 distinct CAR T-cell...
Didier Blaise

RMEI LIGHTNING TALKS

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.

Allergy & Immunology
2021

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.

Gastroenterology
2021

Hematology / Oncology CE Activities

Hematology / oncology blog

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

RMEI Presentations

Optimizing treatment in BCC and CSCC: 3 years of oncology CME

Iterative Data-Driven Education for Evolving Strategies of Care in cSCC

When the Patient Voice is Heard in Education, Does the Clinician Listen?

RMEI DECISION SUPPORT AIDS

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

RMEI LIGHTNING TALKS

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

Previously Published CE Activities